Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors

Published on:

Non-small cell lung cancer

The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.

Read more    Source: medcitynews.com